Jinglu Ai, MD, PhD
Jinglu Ai, MD, PhD, is an associate professor of neurobiology in the Barrow Aneurysm and AVM Research Center.
Dr. Ai’s expertise includes translational research of neurological disorders, including traumatic brain injury and subarachnoid hemorrhage. He is a member of the Stroke Council of the American Heart Association/American Stroke Association and the World Stroke Organization.
Dr. Ai earned both his master’s degree and medical degree from Heilongjiang University of Chinese Medicine and Pharmacy in Harbin, China. He earned a PhD in pathology from the Academy of Chinese Medical Science in Beijing and a PhD in neuroscience from the Roskilde University Center in Denmark. He completed postdoctoral fellowships in neuroscience at Stony Brook University in New York and The Hospital for Sick Children affiliated with the University of Toronto in Canada.
Dr. Ai’s current research interests include translational mechanistic studies on the formation and rupture of aneurysms.
Artak Tovmasyan, PharmD, PhD
Artak Tovmasyan, PharmD, PhD, is an associate professor in the Department of Neurobiology at Barrow Neurological Institute. He directs the pharmacokinetics core laboratory at the Ivy Brain Tumor Center.
Dr. Tovmasyan’s expertise includes pharmaceutical sciences and drug development, particularly in the field of neuro-oncology. He is a member of the American Association for Cancer Research, the Society for Neuro-Oncology, the Society for Redox Biology and Medicine, and the Society for Porphyrins and Phthalocyanines.
Dr. Tovmasyan earned his PharmD and PhD degrees from the Yerevan State Medical University School of Pharmacy in Armenia, where he also completed a residency in drug development. He completed a postdoctoral fellowship in the Department of Radiation Oncology, Division of Cancer Biology at Duke University Medical Center.
Dr. Tovmasyan’s work in the pharmacokinetics core laboratory involves evaluating drugs used in Phase 0 clinical trials for brain tumor patients. The results obtained in this state-of-the-art laboratory enable doctors to implement the most efficient brain tumor treatment regimens. The lab also provides services in the assessment and design of preclinical pharmacokinetics studies for experimental drugs, collection and processing of specimens, publishing guidance, and assistance with grant applications. Dr. Tovmasyan’s research interests also include medicinal chemistry in the design and development of agents that target the brain, particularly novel radio-modulators for brain tumor therapy.
An-Chi Tien, PhD
An-Chi Tien, PhD, is an assistant professor in the Department of Neurobiology at Barrow Neurological Institute. He works in the Ivy Brain Tumor Center.
Dr. Tien’s expertise includes developmental biology and genetics, particularly applied to neuro-oncology. Dr. Tien is a member of the American Brain Tumor Association Alumni Research Network, the American Society of Clinical Oncology, and the Society for Neuro-Oncology.
Dr. Tien earned his doctorate degree in developmental biology from the Baylor College of Medicine in Houston. He completed his postdoctoral research fellowship at University of California San Francisco’s Institute for Regenerative Medicine.
Dr. Tien’s research focuses on establishing and optimizing pharmacodynamic tests to support clinical trials for patients with brain tumors and to better understand tumor resistance mechanisms.
Richard Dortch, PhD
Richard Dortch, PhD, is an associate professor in the Division of Neuroimaging Research at Barrow Neurological Institute.
Dr. Dortch’s expertise includes radiological sciences and biomedical engineering. He is a member of the American Academy of Neurology and the International Society for Magnetic Resonance in Medicine.
Dr. Dortch earned his master’s and doctorate degrees in biomedical engineering from Vanderbilt University in Nashville, Tennessee. He completed a postdoctoral research fellowship in the Department of Radiology and Radiological Sciences at Vanderbilt University Medical Center.
Dr. Dortch’s research interests include developing, optimizing, and validating quantitative MRI methods for the brain, spinal cord, and nerves. He aims to apply these methods in patient populations to guide surgery, improve diagnostics, expand our understanding of disease progression, and serve as biomarkers of therapeutic response.